Extended Data Fig. 4: Experimental design for the evaluation of EIDD-2801 as a treatment or pre-exposure prophylaxis for infection with SARS-CoV-2.
From: SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
a, Experimental design for treatment. LoM were orally administered EIDD-2801 or vehicle at 24 h or 48 h after exposure to SARS-CoV-2, and every 12 h thereafter. Virus titres were measured two days after the initiation of treatment. b, Experimental design for pre-exposure prophylaxis. LoM were orally administered EIDD-2801 or vehicle control 12 h before exposure to SARS-CoV-2, and every 12 h thereafter. Virus titres in human lung tissues were measured two days after exposure.
